Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03501043 · ClinicalTrials.gov registry record · Phase 4
Assessment of Gait After Dysport Treatment
A Phase 4 study, sponsored by Albert Einstein Healthcare Network.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT03501043 is a Phase 4 study that has completed, run by Albert Einstein Healthcare Network. The registered enrollment target is 11 participants.
The verdict
NCT03501043, a Phase 4 study, has completed, sponsored by Albert Einstein Healthcare Network.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
This pilot study will aim to understand the potential benefit of the assessment of walking using video slow motion for muscle selection and the development of an image catalogue guide of the potential results of injection of abobotulinumtoxinA by comparing foot postures before and after injection. The objective is to evaluate the use of video assessment to improve muscle selection for the injection of botulinum toxin A to improve walking outcomes. Primary outcomes include: self-selected velocity (SSV), maximal velocity (MV) and symmetry of walking. Secondary outcomes include: passive range of motion (PROM), Modified Ashworth Scale (MAS) and the Tardieu Scale (TS). Fifteen persons post stroke or TBI over age 18 with equinovarus foot deformity who are able to ambulate will be included in the study. Dysport 1000 to 1500 units will be used to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), tibialis posterior and long toe flexors. The duration of subjects' participation is 4-6 weeks.
Interventions
- DRUG Dysport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-06-11 |
| Est. Completion | 2019-08-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03501043
The ClinicalTrials.gov registry entry for NCT03501043 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein Healthcare Network, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dysport is the first listed.
NCT03501043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03501043 about?
NCT03501043 is a clinical study titled "Assessment of Gait After Dysport Treatment". This pilot study will aim to understand the potential benefit of the assessment of walking using video slow motion for muscle selection and the development of an image catalogue guide of the potential results of injection of abobotulinumtoxinA by comparing foot postures before and after injection. T...
What is the current status of trial NCT03501043?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2018-06-11. Estimated completion is 2019-08-22.
What interventions are being tested in trial NCT03501043?
The interventions under investigation include: Dysport (DRUG).
Who is sponsoring clinical trial NCT03501043?
This trial is sponsored by Albert Einstein Healthcare Network, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.